Lundbeck and Otsuka await important exam results on Friday for potential Alzheimer's drug
Huge financial rewards are at stake for Lundbeck and partner Otsuka today as two expert panels under the US drug authority assess a potential treatment for agitation in Alzheimer’s patients.
by albert rønning-andersson, translated by daniel pedersen
On Friday, a significant hurdle on the way to a billion-dollar market could be cleared for Lundbeck and its collaborator, Otsuka; the companies’ drug candidate is being assessed by two advisory expert panels to the US Food and Drug Administration (FDA).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
